EMA (EU)
EVENT
European Medicines Agency workshop on bacteriophage therapy
Published: 10/30/2026Detected: 10/22/2026
Summary preview
Discusses how an EU framework under the new EU pharmaceutical legislation could better accommodate phage therapy’s personalized/strain-adaptive nature, including practical regulatory principles to balance innovation…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
manufacturing
quality
clinical
safety
labeling
#bacteriophage therapy
#phage therapy
#multidrug-resistant bacteria
#EU pharmaceutical legislation
#delegated acts
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- SME info day - navigating EMA support: From innovation to marketing authorisation11/6/2026
- 2026 annual open meeting of the European Network of Paediatric Research at EMA (EnprEMA)11/5/2026
- EMA paediatric investigation plans in-person training course11/5/2026
- Committee for Advanced Therapies (CAT): 4-6 November 202611/4/2026
- EMA Methodology Working Party interested parties meeting 202611/4/2026